

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	O. CONFIRMATION NO	
09/511,939	02/24/2000	Ian Tomlinson	3789/86470	5170	
29933 7	02/13/2003				
PALMER &	DODGE, LLP		EXAMI	EXAMINER URI, PADMASHRI	
	M. WILLIAMS GTON AVENUE		PONNALURI, I		
BOSTON, MA	A 02199		ART UNIT	PAPER NUMBER	
			1639	17	
			DATE MAILED: 02/13/2003	,0	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary		09/511,939	Tomlinson et al					
		Examiner		Art Unit				
P	estricted Purposes Only	Padmashri Ponr		1639				
/\_	The MAILING DATE of this communication appears	on the cover sheet wit	th the corres	spondence addre	ess			
Period f	or Reply							
A SHO	ORTENED STATUTORY PERIOD FOR REPLY IS SET	TO EXPIRE1	MONTH	H(S) FROM				
IHE N - Extensi	MAILING DATE OF THIS COMMUNICATION. ons of time may be available under the provisions of 37 CFR 1.136 (a). In	no event, however, may a rep	ly be timely filed	l after SIX (6) MONTH	S from the			
mailing	date of this communication.	he statutory minimum of thirty	(30) days will b	e considered timely.				
- If NO p	eriod for reply is specified above, the maximum statutory period will apply to reply within the set or extended period for reply will, by statute, cause t	and will expire SIX (6) MONTH the application to become ABAI	S from the maili NDONED (35 U.S	ng date of this commu S.C. § 133).	inication.			
- Any re	bly received by the Office later than three months after the mailing date of patent term adjustment. See 37 CFR 1.704(b).	this communication, even if time	nely filed, may re	educe any				
Status								
1) 💢	Responsive to communication(s) filed on Nov 26,	2002	<u> </u>		·			
2a) 🗌	This action is <b>FINAL</b> . 2b) $\mathbf{X}$ This ac	tion is non-final.						
3) 🗆	Since this application is in condition for allowance closed in accordance with the practice under $Ex\ partial$	except for formal ma arte Quayle, 1935 C.	tters, prose D. 11; 453	ecution as to th O.G. 213.	e merits is			
Disposi	tion of Claims							
	Claim(s) <u>32-52</u>							
4	a) Of the above, claim(s) 32		is/aı	re withdrawn fr	rom consideration.			
5) 🗆	Claim(s)			is/are allowed				
6) 🗌	Claim(s)			is/are rejected	•			
7) 🗆	Claim(s)			is/are objected	i to.			
8) 💢	Claims <u>33-52</u> are subject to restriction and/or election requirement.							
Applica	tion Papers							
9) 🗆	The specification is objected to by the Examiner.							
10)		d on is/are a) accepted or b) objected to by the Examiner.						
_	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
11)			approved	o) 🗆 disappro	ved by the Examiner.			
- —	If approved, corrected drawings are required in reply							
12)	The oath or declaration is objected to by the Exan	niner.						
	under 35 U.S.C. §§ 119 and 120  Acknowledgement is made of a claim for foreign	oriority under 35 H.S.	C § 119(a	)-(d) or (f).				
	$\square$ All b) $\square$ Some* c) $\square$ None of:	priority and or or ore		, (0) 0: (:/:				
a, c	1. ☐ Certified copies of the priority documents ha	ve heen received.						
	2. Certified copies of the priority documents ha		Application	No.				
	3. Copies of the certified copies of the priority				Stage			
*5	application from the International Bur see the attached detailed Office action for a list of t	eau (PCT Rule 17.2(a	3)).					
14)	<u> </u>							
a)[								
15)	Acknowledgement is made of a claim for domesti	ic priority under 35 U	.S.C. §§ 12	20 and/or 121.				
Attachn		4) Interview Summary	(PTO-413) Pana	ır No(s).				
_	otice of References Cited (PTO-892) otice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal P		•				
_,,								

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).

6) Other:

Art Unit: 1639

## **DETAILED ACTION**

1. Applicant's election with traverse of Group I, claims 1-13 and species election of super antigen as generic ligand; antibody as binding polypeptide; and antigen as target ligand, in Paper No. 17, filed on 11/26/02 is acknowledged. The traversal is on the ground(s) that the search for Group II inventions are unduly burdensome, and group II claims are dependent on the group I claim 1. This is not found persuasive because group II inventions are drawn to methods which is patentably distinct from the elected group I. Further it is noted that claims 1-14 have been canceled and replaced with new claims. Thus, applicants arguments are moot in view of the amendments.

The requirement is still deemed proper and is therefore made FINAL.

- 2. The amendment filed on 11/26/02 has been fully considered and entered into the application.
- 3. New claims 33-52 have been added and claims 1-14 have been canceled by the amendment filed on 11/26/02. Note that claims 15-31 have been canceled by the amendment filed on 10/19/01.
- 4. Claims 32-52 are currently pending in this application.
- 5. Claim 32 is withdrawn from further consideration pursuant to 37 CAR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in Paper No. 9.
- 6. Claims 33-52 are currently being examined in this application.

Art Unit: 1639

7. The newly added claims 33-52 have patentably distinct species and the following election of species is required.

Please Note: In an effort to enhance communication with our customers and reduce processing time, a dedicated Fax machine is in place to receive your responses. The Fax number is 703-308-4315. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program. If you have any questions or suggestions please contact Andrew Wang, Supervisory Patent Examiner at andrew.wang@uspto.gov or 7(703)306-3217. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions.

## Election/Restriction

- 8. This application contains claims directed to the following patentably distinct species of the claimed invention: Applicants are requested to elect a single species of the following:
- a) a single species of generic ligand from claim 43 (note that applicants have elected super antigen as generic ligand);
- b) a single species of binding polypeptide from claim 38 (note that applicants have elected antibody as binding polypeptide);

Art Unit: 1639

a single species of target ligand (note that antigen is not specific, since the generic ligand is specific superantigen, applicants are requested to elect a single species of target which specifically binds to the superantigen);

d) a single species of second generic ligand (if it is different from generic ligand)

NOTE that claims 33 and 52 recite a second generic ligand, it may be same or different from the generic ligand.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 33-35, 40-52 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CAR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the

Art Unit: 1639

examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 9. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CAR 1.143).
- 10. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CAR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CAR 1.48(b) and by the fee required under 37 CAR 1.17(I).
- 11. Applicant is required to reply to this restriction requirement within 30 days of mailing this action. See MPEP 809.2(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to P. Ponnaluri whose telephone number is (703) 305-3884. The examiner is on *Increased Flex Schedule* and can normally be reached on Monday to Friday from 7.00 AM to 3.30 PM.

Art Unit: 1639

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang, can be reached on (703) 306-3217. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

P. Ponnaluri Patent Examiner Technology Center 1600 Art Unit 1639 11 February 2003

PADMASHRI PONNALURI PRIMARY EXAMINER